This is a preview of subscription content, log in via an institution to check access.
Reference
Vreman RA, et al. Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. Applied Health Economics and Health Policy : 18 Jul 2019. Available from: URL: http://doi.org/10.1007/s40258-019-00496-1
Rights and permissions
About this article
Cite this article
Acalabrutinib not cost effective in chronic lymphocytic leukaemia. PharmacoEcon Outcomes News 834, 2 (2019). https://doi.org/10.1007/s40274-019-6102-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-6102-4